NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $2.71 +0.12 (+4.63%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$2.88 +0.17 (+6.16%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NRx Pharmaceuticals Stock (NASDAQ:NRXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.48▼$2.7750-Day Range$2.59▼$3.6752-Week Range$1.62▼$5.05Volume1.18 million shsAverage Volume623,970 shsMarket Capitalization$117.34 millionP/E RatioN/ADividend YieldN/APrice Target$34.50Consensus RatingModerate Buy Company Overview NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations. NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior. The company has also evaluated ketamine-based therapies, including NRX-100, and has pursued ZYESAMI (aviptadil), an investigational treatment for respiratory failure associated with critical COVID-19. Regulatory approval and commercial availability may vary by product and indication. The company traces its origins to NeuroRx, which combined with Big Rock Partners Acquisition Corp. in 2021 in a transaction that resulted in the public company now known as NRx Pharmaceuticals. Its development activities have primarily centered on clinical research and regulatory programs in the United States, with studies and collaborations involving international locations. NRx is led by founder Jonathan Javitt, who has served in senior executive and scientific roles at the company.AI Generated. May Contain Errors. Read More NRx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreNRXP MarketRank™: 2.19537815126 of 5 starsNRx Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 516th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNRx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialNRx Pharmaceuticals has a consensus price target of $34.50, representing about 1,173.1% upside from its current price of $2.71.Amount of Analyst CoverageNRx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NRx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.14) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.17% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 13.98, which indicates bearish sentiment.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 0.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.60 News SentimentNRx Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NRx Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest8 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows5 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of NRx Pharmaceuticals is held by insiders.Percentage Held by Institutions4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXP Stock News HeadlinesNRx Pharmaceuticals Targets November FDA Deadline For Preservative-Free KetamineOctober 15 at 5:25 PM | rttnews.comNRx Pharmaceuticals Receives FDA Label Revision Request For Its Preservative-Free Ketamine ProductOctober 15 at 12:23 PM | rttnews.comElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation. | Paradigm Press (Ad)NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineOctober 15 at 8:27 AM | globenewswire.comQ3 EPS Estimate for NRx Pharmaceuticals Lowered by AnalystOctober 6, 2026 | americanbankingnews.comNRx (NASDAQ: NRXP) secures DARPA contract for depression trial and $11.2 million awardOctober 6, 2026 | americanbankingnews.comAstrazeneca (NYSE:AZN) & NRx Pharmaceuticals (NASDAQ:NRXP) Head to Head ReviewOctober 5, 2026 | americanbankingnews.comNRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for ...September 30, 2026 | markets.businessinsider.comSee More Headlines NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $2.71 at the beginning of 2026. Since then, NRXP shares have increased by 0.0% and is now trading at $2.71. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) released its quarterly earnings results on Friday, August, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.33. The company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.33 million. Read the conference call transcript. When did NRx Pharmaceuticals' stock split? Shares of NRx Pharmaceuticals reverse split before market open on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), NIO (NIO), Advanced Micro Devices (AMD), Tesla (TSLA), Palantir Technologies (PLTR), Plug Power (PLUG) and Super Micro Computer (SMCI). Company Calendar Last Earnings8/14/2026Today10/15/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, NRXP's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NRXP CIK1719406 Webnrxpharma.com Phone(484) 254-6134FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for NRx Pharmaceuticals$34.50 High Price Target$49.00 Low Price Target$10.00 Potential Upside/Downside+1,173.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.62 million Net Margins-691.81% Pretax Margin-692.13% Return on EquityN/A Return on Assets-63.92% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual Sales$1.23 million Price / Sales95.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-5.02Miscellaneous Outstanding Shares43,300,000Free Float40,525,000Market Cap$117.34 million OptionableOptionable Beta2.07 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NRXP) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRXP Stock Alerts